---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-012281"
form_type: "8-K"
ticker: "MBOT"
cik: "0000883975"
company_name: "Microbot Medical Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:18:24.703391+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Microbot Medical's LIBERTY pivotal study published in JVIR; full market launch in April 2026

## Summary
- ACCESS-PVI study published in JVIR, a top radiology journal, after independent peer review.
- LIBERTY received FDA clearance in Sep 2025; limited market release started late 2025.
- Full commercial launch planned at SIR conference in April 2026 to expand adoption.
- Dr. Francois Cornelis, first author, was Lead PI for the multicenter feasibility study.
- LIBERTY is first FDA-cleared single-use robotic system for peripheral endovascular procedures.

## SEC filing metadata
- accession: 0001493152-26-012281
- form_type: 8-K
- ticker: MBOT
- cik: 0000883975
- company_name: Microbot Medical Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/883975/000149315226012281/0001493152-26-012281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/883975/000149315226012281/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-012281
- JSON: https://secwatch.observer/filing/0001493152-26-012281.json
- Plain text: https://secwatch.observer/filing/0001493152-26-012281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.